{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P08235",
      "entity_text" : "mCR",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9NRJ3",
      "entity_text" : "MEC",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The MEC regimen (MEC; mitoxantrone 6 mg/m 2 on days 1-4, etoposide 80 mg/m 2 on days 1-5, and acytarabine 100 mg/m 2 on days 1-5) and gemtuzumab ozogamicin (GO 3 mg/m 2) induced third mCR.",
  "reading_complete" : "2020-08-03T17:39:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T17:38:49Z",
  "trigger" : "induced",
  "evidence" : [ "MEC regimen (MEC; mitoxantrone 6 mg/m 2  on days 1-4, etoposide 80 mg/m 2  on days 1-5, and acytarabine 100 mg/m 2  on days 1-5) and gemtuzumab ozogamicin (GO 3 mg/m 2 ) induced third mCR" ],
  "pmc_id" : "5412762",
  "score" : 0
}